BACKGROUND: A common functional polymorphism of the brain-derived neurotrophic factor gene (BDNF Val66Met) was previously associated with diminished episodic memory performance in healthy people. As cognitive function is commonly impaired in patients with systemic lupus erythematosus (SLE), the association of the BDNF Val66Met with neurocognitive function was studied. OBJECTIVE: To study the association of the BDNF Val66Met with neurocognitive function in a cohort of patients with SLE. METHODS: Cognitive function was assessed in 59 patients with SLE with no previous or current central nervous system involvement. Cognitive tests were grouped into five domains (memory, attention/executive function, visuospatial skills, motor function and psychomotor speed) and used to obtain domain Z scores, reflecting the difference between averaged scores of performance on individual tests and published norms in each domain. Genotyping was carried out using a 5'-nuclease assay with 99.9% accuracy. Unpaired t test was used to assess the relationship between genotypes and cognitive function, whereas the effect of possible confounders was assessed in a multivariate analysis. RESULTS: Patients carrying the Met66 allele scored significantly higher on psychomotor, attention/executive and motor function tests, resulting in significantly higher domain Z scores for the psychomotor (p = 0.005) and motor (p = 0.002) domains. CONCLUSIONS: The BDNF Met66 allele was associated with better cognitive functioning in the psychomotor and motor domains, even after controlling for differences in ethnicity, sex, depression status and prednisone treatment. These data suggest that the BDNF Met66 allele confers protection against the decline of motor and psychomotor cognitive functions in patients with longstanding SLE.
BACKGROUND: A common functional polymorphism of the brain-derived neurotrophic factor gene (BDNF Val66Met) was previously associated with diminished episodic memory performance in healthy people. As cognitive function is commonly impaired in patients with systemic lupus erythematosus (SLE), the association of the BDNF Val66Met with neurocognitive function was studied. OBJECTIVE: To study the association of the BDNF Val66Met with neurocognitive function in a cohort of patients with SLE. METHODS: Cognitive function was assessed in 59 patients with SLE with no previous or current central nervous system involvement. Cognitive tests were grouped into five domains (memory, attention/executive function, visuospatial skills, motor function and psychomotor speed) and used to obtain domain Z scores, reflecting the difference between averaged scores of performance on individual tests and published norms in each domain. Genotyping was carried out using a 5'-nuclease assay with 99.9% accuracy. Unpaired t test was used to assess the relationship between genotypes and cognitive function, whereas the effect of possible confounders was assessed in a multivariate analysis. RESULTS:Patients carrying the Met66 allele scored significantly higher on psychomotor, attention/executive and motor function tests, resulting in significantly higher domain Z scores for the psychomotor (p = 0.005) and motor (p = 0.002) domains. CONCLUSIONS: The BDNF Met66 allele was associated with better cognitive functioning in the psychomotor and motor domains, even after controlling for differences in ethnicity, sex, depression status and prednisone treatment. These data suggest that the BDNF Met66 allele confers protection against the decline of motor and psychomotor cognitive functions in patients with longstanding SLE.
Authors: R Monastero; P Bettini; E Del Zotto; E Cottini; A Tincani; G Balestrieri; R Cattaneo; R Camarda; L A Vignolo; A Padovani Journal: J Neurol Sci Date: 2001-02-15 Impact factor: 3.181
Authors: Larissa Lapteva; Miroslawa Nowak; Cheryl H Yarboro; Kazuki Takada; Tresa Roebuck-Spencer; Thomas Weickert; Joseph Bleiberg; Donald Rosenstein; Maryland Pao; Nicholas Patronas; Sonya Steele; Melissa Manzano; Jan Willem C van der Veen; Peter E Lipsky; Stefano Marenco; Robert Wesley; Bruce Volpe; Betty Diamond; Gabor G Illei Journal: Arthritis Rheum Date: 2006-08
Authors: R L Brey; S L Holliday; A R Saklad; M G Navarrete; D Hermosillo-Romo; C L Stallworth; C R Valdez; A Escalante; I del Rincón; G Gronseth; C B Rhine; P Padilla; D McGlasson Journal: Neurology Date: 2002-04-23 Impact factor: 9.910
Authors: Frank Krueger; Matteo Pardini; Edward D Huey; Vanessa Raymont; Jeffrey Solomon; Robert H Lipsky; Colin A Hodgkinson; David Goldman; Jordan Grafman Journal: J Neurosci Date: 2011-01-12 Impact factor: 6.167
Authors: Brian Barton; Andrew Treister; Melanie Humphrey; Garen Abedi; Steven C Cramer; Alyssa A Brewer Journal: J Vis Date: 2014-08-07 Impact factor: 2.240